Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses.

Mesenchymal stem cells (MSCs) suppress alloantigen-induced T-cell functions in vitro and infusion of third-party MSCs seems to be a promising therapy for graft-versus-host disease (GVHD). Little is known about the specificity of immunosuppression by MSCs, in particular the effect on immunity to pathogens. We have studied how MSCs affect T-cell responses specific to Epstein-Barr virus (EBV) and cytomegalovirus (CMV). We found that EBV- and CMV-induced proliferation and interferon-gamma (IFN-gamma) production from peripheral blood mononuclear cells (PBMCs) was less affected by third-party MSCs than the response to alloantigen and that MSCs had no effect on expansion of EBV and CMV pentamer-specific T cells. Established EBV-specific cytotoxic T cells (CTL) or CMV-CTL cultured with MSCs retained the ability to proliferate and produce IFN-gamma in response to their cognate antigen and to kill virally infected targets. Finally, PBMCs from 2 patients who received MSCs for acute GVHD showed persistence of CMV-specific T cells and retained IFN-gamma response to CMV after MSC infusion. In summary, MSCs have little effect on T-cell responses to EBV and CMV, which contrasts to their strong immunosuppressive effects on alloreactive T cells. These data have major implications for immunotherapy of GVHD with MSCs and suggest that the effector functions of virus-specific T cells may be retained after MSC infusion.

[1]  N. Rouas-Freiss,et al.  Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.

[2]  Franco Locatelli,et al.  Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. , 2007, Blood.

[3]  V. Levitsky,et al.  Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes , 2007, Journal of leukocyte biology.

[4]  A. Cope,et al.  The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells1 , 2007, The Journal of Immunology.

[5]  M. Haniffa,et al.  Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells1 , 2007, The Journal of Immunology.

[6]  P. Veys,et al.  Generation of Trispecific Cytotoxic T Cells Recognizing Cytomegalovirus, Adenovirus, and Epstein-Barr Virus: An Approach for Adoptive Immunotherapy of Multiple Pathogens , 2007, Journal of immunotherapy.

[7]  A. Poggi,et al.  Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. , 2007, Haematologica.

[8]  O. Ringdén,et al.  Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual , 2006, Bone Marrow Transplantation.

[9]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[10]  J. Galipeau,et al.  Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. , 2006, Blood.

[11]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[12]  P. Rameshwar,et al.  A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. , 2005, Experimental hematology.

[13]  N. Le,et al.  Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. , 2005, Cytotherapy.

[14]  Roland Meisel,et al.  Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. , 2004, Blood.

[15]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[16]  S. Haynesworth,et al.  Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation , 2004, Bone Marrow Transplantation.

[17]  O. Ringdén,et al.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.

[18]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[19]  P. Rameshwar,et al.  Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens1 , 2003, The Journal of Immunology.

[20]  M. Krampera,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[21]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[22]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[23]  J. Spivak.  Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.

[24]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Craddock,et al.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.

[26]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[27]  Zhensheng Liu,et al.  Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. , 2001, Transplantation.

[28]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[29]  S. Nantel,et al.  Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience , 1998, Bone Marrow Transplantation.

[30]  K. Cornetta,et al.  Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. , 1998, Blood.

[31]  R. Macklis,et al.  Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. , 1991, Blood.

[32]  O. Ringdén,et al.  Induction of Immunoglobulin Secretion and DNA Synthesis in Human Lymphocytes in Vitro by Cytomegalovirus Preparations , 1986, Scandinavian journal of immunology.

[33]  H. Balfour,et al.  Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. , 1986, Blood.

[34]  M. Bevan,et al.  Antigen recognition by cloned cytotoxic T lymphocytes follows rules predicted by the altered-self hypothesis , 1982, The Journal of experimental medicine.

[35]  N. Flournoy,et al.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. , 1980, The Journal of infectious diseases.

[36]  C. Briani,et al.  Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes: not always a POEMS syndrome. , 2006, Haematologica.

[37]  O. Ringdén,et al.  Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.